ASCO: Cetuximab Ups Survival Over Bevacizumab in Colorectal Cancer
Results from the German AIO KRK-0306 study, FIRE-3, show that the addition of cetuximab (Erbitux) to chemotherapy rather than bevacizumab (Avastin) increased overall survival by nearly 4 months in patients with KRAS wild-type metastatic colorectal cancer.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Erbitux | Study